摘要
目的对带量采购政策实施前后医药制造业技术创新效率进行比较研究,评估国家重大战略在药品研发创新模块的执行成效,为加大政策在各地区深入落实的推行力度提供重要参考,也为医药制造业创新效率的增长提供助推作用。方法利用DEA-Malmquist指数方法对2014-2021年全国30个省(自治区、直辖市)的医药制造业技术创新效率进行分阶段实证分析。结果带量采购政策实施后,我国医药制造业创新水平仍有较大发展空间,主要受纯技术效率影响,且不同区域间研发创新各项效率指标存在较大差异性,技术创新效率与行业收益情况不成正比。结论医药制造业应积极参与带量采购,转变发展战略,科学配置创新资源,提高投入产出比例。相关政府部门可出台鼓励研究创新的制度措施,充分发挥其政策导向作用,增强带量采购政策对于医药制造业在研发创新领域的实施效果,完善国家对于技术创新的支持机制。
Objective To conduct a comparative study on the technological innovation efficiency of the pharmaceutical manufacturing industry in 30 provinces and cities before and after the implementation of the centralized drug quantity procurement policy,to evaluate the implementation effect of the national major strategy of centralized drug quantity procurement policy in the drug research and development innovation module,which would provide an important reference for the further implementation of the policy in various regions,and provide a boost for the improvement of innovation efficiency of pharmaceutical manufacturing industry.Methods DEAMalmquist index method was used to conduct a phased empirical analysis of the technological innovation efficiency of the pharmaceutical manufacturing industry in 30 provinces and cities in China from 2014 to 2021.Results After the implementation of the policy of centralized drug quantity procurement,there was still more room for the development of the innovation level of Chinese pharmaceutical manufacturing industry,which was mainly influenced by pure technical efficiency.There were great differences in the various efficiency indicators of R&D innovation among different regions,and the efficiency of technological innovation was not directly proportional to the industry revenue situation.Conclusion The pharmaceutical manufacturing industry should actively participate in centralized drug quantity procurement,transform development strategies,scientifically allocate innovative resources,and increase the input-output ratio.During the implementation process,relevant government departments can introduce institutional measures to encourage research and innovation,fully leverage its policy guidance role,enhance the implementation effect of the policy on R&D innovation in the pharmaceutical manufacturing industry,and improve the national support mechanism for technological innovation.
作者
葛雅芬
阮娴静
郑莉
GE Yafen;RUAN Xianjing;ZHENG Li(Schoolof Medical Business,Guangdong Pharmaceutical University,Guangzhou 510006,China)
出处
《广东药科大学学报》
CAS
2023年第3期7-15,共9页
Journal of Guangdong Pharmaceutical University
基金
广东省教育科学规划课题(高等教育专项)基金资助(2021GXJK332)。
关键词
带量采购
医药制造业
DEA-MALMQUIST指数
效率评价
centralized drug quantity procurement
pharmaceutical manufacturing
DEA-Malmquist index
efficiency evaluation
